Hikma appoints Umang Vohra as a Director
London, 9 November 2026 – Hikma Pharmaceuticals PLC (Hikma) announces the appointment of Umang Vohra as an independent Non-Executive Director with effect from 1 December 2026. Umang will also be appointed a member of the Audit Committee and Nomination and Governance Committee with effect from 1 December 2026.
Commenting on the appointment, Victoria Hull, Chair said “I am delighted to welcome Umang to the Hikma Board. Umang is an experienced CEO with deep knowledge of the generic pharmaceutical market and an impressive track record in growth, innovation, portfolio development and transformation. His extensive international experience, particularly in North America, will bring valuable perspective to the Board.”
About Umang Vohra
Umang currently serves as Chair and Chief Executive Officer of Cohance Lifesciences Limited, an end-to-end innovation-led CDMO business listed in India. In this role he divides his time between the US and India.
Umang is also an independent board member of AGS Health, a revenue cycle management company registered in India.
Umang previously served as CEO of Cipla Limited and is credited with transforming Cipla into a diversified global pharmaceutical enterprise. Earlier in his career, Umang held senior finance, business development and operational leadership roles at Dr. Reddy’s Laboratories Limited, including as CFO and Head of its North American business.